E
Annovis Bio, Inc. ANVS
$1.57 -$0.07-4.27% NYSE
Recommendation
Prev Close
$1.64
Volume
269,278
Avg Vol (90D)
475,669
Market Cap
$31.96M
Dividend & Yield
--
52-Week Range
$1.11 - $20.00
P/E (TTM)
--
EPS (TTM)
-$3.33
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Annovis Bio, Inc. (NYSE:ANVS) Given Average Recommendation of "Buy" by Analysts
4/3/2025 - Ticker Report
Annovis Bio (ANVS) Faces NYSE Compliance Challenge
3/27/2025 - GuruFocus
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
3/27/2025 - GuruFocus
Annovis Bio receives noncompliance notification from NYSE
3/27/2025 - TipRanks Financial Blog
Annovis Bio Faces NYSE Non-Compliance Notice
3/27/2025 - TipRanks Financial Blog
Annovis Bio receives noncompliance notification from NYSE
3/27/2025 - The Fly
Annovis Bio receives NYSE notice over non-compliance with listing rules
3/27/2025 - Seeking Alpha - Healthcare
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
3/27/2025 - Globe Newswire
Annovis to Attend AD/PD 2025 with Extensive Scientific Program
3/25/2025 - Globe Newswire
Annovis Bio (NYSE:ANVS) Releases Earnings Results, Misses Expectations By $0.05 EPS
3/23/2025 - Ticker Report
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
3/21/2025 - GuruFocus
Annovis Bio reports Q4 EPS (43c) vs. ($2.24) last year
3/21/2025 - TipRanks Financial Blog
Annovis Bio reports Q4 EPS (43c) vs. ($2.24) last year
3/21/2025 - The Fly
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
3/21/2025 - Globe Newswire
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment
3/11/2025 - Globe Newswire
Annovis to Host Patients' Live Forum on February 27, 2025
2/19/2025 - Globe Newswire
Annovis Bio just downgraded at D. Boral Capital, here's why
2/10/2025 - The Fly
Analysts Set Annovis Bio, Inc. (NYSE:ANVS) PT at $31.40
2/8/2025 - Ticker Report
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
2/7/2025 - Globe Newswire
Annovis Bio announces first patients entered Phase 3 study of buntanetap
2/5/2025 - TipRanks Financial Blog
Annovis Bio announces first patients entered Phase 3 study of buntanetap
2/5/2025 - The Fly
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease
2/5/2025 - Globe Newswire
We Did The Math IWC Can Go To $181
2/5/2025 - ETF Channel
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
2/4/2025 - Globe Newswire
Annovis Bio falls -25.6%
2/3/2025 - The Fly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$26.69M
Net Income (TTM)
-$24.59M
Balance Sheet
Total Assets (Q)
$13.93M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$4.62M
Book Value Per Share (Q)
$0.6582
Cash Flow
Cash from Operations (TTM)
-$21.89M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$26.69M
Net Change in Cash (TTM)
$4.80M
Filings
Filing Date
Friday, March 21, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
2.03
7-Day Total Return
28.69%
30-Day Total Return
-4.85%
60-Day Total Return
-67.89%
90-Day Total Return
-71.76%
Year to Date Total Return
-69.28%
1-Year Total Return
-88.46%
2-Year Total Return
-89.37%
3-Year Total Return
-86.68%
5-Year Total Return
-59.95%
52-week Low
Apr 09, 2025 - $1.11
52-week High
Apr 29, 2024 - $20.00
Valuation
Market Cap
$31.96M - Nano Cap
Enterprise Value
$21.41M
Price/Sales (TTM)
--
Price/Book (Q)
2.49
Dividends and Shares
Shares Outstanding
13.79M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.annovisbio.com
Phone Number
484 875 3192
Address
101 Lindenwood Drive
Malvern, PA 19355
Country
United States
Year Founded
2008
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase... more
NYSE 04/25/2025 4:00PM Eastern Quotes delayed